A new, further attenuated measles vaccine, developed by propagation of Edmonston B measles virus in the chorioallantoic membrane in ovo, has been clinically evaluated in children and found to compare favorably with a commercially available product. The vaccine is prepared in chick embryo tissue culture and appears to possess noteworthy stability at 4 C.
The adaptation of the Edmonston B strain of measles virus (3) to growth on the chorioallantoic membrane (CAM) of the embryonated hen egg has been reported previously from these laboratories (1) . The 68th and 81st passage levels of CAM measles virus were used as seed to produce vaccines in 1966, and were tested in small clinical trials (unpublished data) which indicated that, if an acceptable level for antigenicity and more diminished reaction rates existed, it would lie within these passage limits. This conclusion was based on the observation that the 68th passage vaccine retained characteristics of the parent Edmonston strain, whereas the 81st passage exhibited properties of over-attenuation. This paper reports on the development of vaccines at the intermediate passage levels and on their evaluation in clinical studies of 3,000 children to determine the optimal passage level for vaccine production. MATERIALS Observations on fever and rash throughout the study period are presented in Tables 3 and  4 . The total incidence of fever and rash for nonsusceptible individuals inoculated with levels 70 through 78 was subtracted to correct the incidence in susceptible children for these groups, since all were part of a double-blind, randomized study. The study conducted with Schwarz vaccine was neither blind nor randomized, and therefore the incidence in nonsusceptible Schwarz recipients only was used to obtain the corrected incidence in susceptible children for this group. It is evident that a reduction in the incidence of rash and fever occurred at level 76. Both levels 76 and 78 appeared comparable to the Schwarz control; however, levels 70, 72, and 74 manifested significantly higher incidences.
Fever associated with level 76 vaccine had an average day of onset at 8 days and, with Schwarz vaccine, at 9 days. The average duration of fever was 1.6 and 1.3 days, respectively. Average onset of rash was day 10 for level 76 and day 9 for Schwarz vaccine. Average duration of rash was 4.3 and 4.9 days, respectively. The other CAM vaccine levels did not differ significantly from level 76 in onset or duration of rash and fever.
Antibody titer. The apparent change in virulence at level 76 also correlates with the geometric mean antibody titers (GMT) shown in Table  5 (Table 6 ) indicated that the decrease in antibody titer with time is consistent with previous reports in the literature (6) . Stability. During the course of this study, it was noticed that lyophilized, stabilized vaccines which had been prepared at the 68th and 81st levels showed no detectable loss of infectivity after 5 to 6 years of storage at 4 C ( Table 7) . Previous reports in the literature indicated that some loss at 4 C after 1 to 2 years could be expected with lyophilized attenuated Edmonston strain virus (4). When level 76 was titrated after 2 years at 4 C, there was no detectable loss in infectivity.
Expanded stability studies on freshly dried production lots of vaccine level 76 are in progress to determine the loss of infectivity at higher temperatures.
DISCUSSION
The data presented indicate that passage of Edmonston B measles vaccine in the chorioallantoic membrane of hen eggs has resulted, after 76 passages, in a vaccine which produces 
